Patents by Inventor Galla Chandra Rao

Galla Chandra Rao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10365266
    Abstract: The disclosed invention includes methods and kits for the removal of white blood cells from samples of immunomagnetically enriched rare cells by treating the sample with a leukocyte marker conjugated to a hapten which adheres to the white blood cells and treating the resulting product with a second medium that adheres to the hapten of the white blood cells that are labeled with the leukocyte marker conjugated to hapten and removing the labeled white blood cells.
    Type: Grant
    Filed: October 11, 2017
    Date of Patent: July 30, 2019
    Assignee: Menarini Silicon Biosystems, Inc.
    Inventors: Galla Chandra Rao, Brad Foulk, Denis Smirnov, Karl Nielsen
  • Publication number: 20190107542
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Application
    Filed: November 30, 2018
    Publication date: April 11, 2019
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Patent number: 10161939
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Grant
    Filed: May 31, 2013
    Date of Patent: December 25, 2018
    Assignees: Duke University, Janssen Diagnostics, LLC
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Publication number: 20180231560
    Abstract: This disclosure provides compositions and methods for the isolation of cells that express c-MET, and in particular circulating tumor cells that express c-MET. The methods can include contacting a biological sample including a c-MET circulating tumor cell with an unbound complex including a capture binding species linked to a solid phase for a time sufficient to allow the unbound complex to bind an extracellular binding domain of the c-MET protein to form a bound complex, and subsequently isolating the bound complex. Compositions, systems, and kits adapted for use with these methods are also provided.
    Type: Application
    Filed: September 15, 2015
    Publication date: August 16, 2018
    Inventors: Galla Chandra Rao, Mark C. Connelly, Rengasamy BOOMINATHAN, Tian Zhang, Mariano A. Garcia-Blanco, Andrew J. Armstrong
  • Publication number: 20180045712
    Abstract: The disclosed invention includes methods and kits for the removal of white blood cells from samples of immunomagnetically enriched rare cells by treating the sample with a leukocyte marker conjugated to a hapten which adheres to the white blood cells and treating the resulting product with a second medium that adheres to the hapten of the white blood cells that are labeled with the leukocyte marker conjugated to hapten and removing the labeled white blood cells.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 15, 2018
    Applicant: Menarini Silicon Biosystems, Inc.
    Inventors: Galla Chandra RAO, Brad FOULK, Denis SMIRNOV, Karl NIELSEN
  • Patent number: 9823238
    Abstract: The disclosed invention includes methods and kits for the removal of white blood cells from samples of immunomagnetically enriched rare cells by treating the sample with a leukocyte marker conjugated to a hapten which adheres to the white blood cells and treating the resulting product with a second medium that adheres to the hapten of the white blood cells that are labeled with the leukocyte marker conjugated to hapten and removing the labeled white blood cells.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: November 21, 2017
    Assignee: Menarini Silicon Biosystems, Inc.
    Inventors: Galla Chandra Rao, Brad Foulk, Denis Smirnov, Karl Nielsen
  • Patent number: 9618515
    Abstract: The invention includes methods for isolating circulating multiple myeloma cells as well as method of treating patients suspected of having diseases of abnormal plasma cells.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: April 11, 2017
    Assignee: Janssen Diagnostics, LLC
    Inventors: Steven Gross, Mark Carle Connelly, Galla Chandra Rao, Marielena Mata, Carrie Morano
  • Publication number: 20160347840
    Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
    Type: Application
    Filed: May 6, 2016
    Publication date: December 1, 2016
    Inventors: Glenn Anderson, Rosa Cardoso, Michael Diem, Francois Gaudet, Shalom Goldberg, Benjamin Harman, Linus Hyun, Steven Jacobs, Donna Klein, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jill Mooney, Jennifer Nemeth-Seay, Karyn O'Neil, Steven Pomerantz, Galla Chandra Rao, Tracy Spinka-Doms, Alexey Teplyakov, Leopoldo Luistro, Sheng-Jiun Wu
  • Publication number: 20160077097
    Abstract: Provided are methods for detecting or isolating circulating tumor cells (CTCs) in a subject. The methods may include detecting the expression of at least one epithelial mesenchymal transition (EMT) biomarker. Further provided are kits for detecting or isolating CTCs. The kits may include antibodies to at least one EMT biomarker. Further provided are methods of predicting the responsiveness of a subject to a cancer drug, methods of targeting delivery of a cancer drug in a subject, methods of providing a cancer prognosis to a subject, and methods for following the progress of cancer in a subject.
    Type: Application
    Filed: May 31, 2013
    Publication date: March 17, 2016
    Inventors: Galla Chandra Rao, Mark C. Connelly, Mariano A. Garcia-Blanco, Andrew J. Armstrong, Rhonda L. Bitting
  • Publication number: 20140335542
    Abstract: The disclosed invention includes methods and kits for the removal of white blood cells from samples of enriched rare cells.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 13, 2014
    Inventors: Galla Chandra Rao, Brad Foulk, Denis Smirnov
  • Publication number: 20130189675
    Abstract: The invention includes methods for isolating circulating multiple myeloma cells as well as method of treating patients suspected of having diseases of abnormal plasma cells.
    Type: Application
    Filed: July 20, 2012
    Publication date: July 25, 2013
    Inventors: Steven Gross, Mark Carle Connelly, Galla Chandra Rao, Marielena Mata, Carrie Morano
  • Publication number: 20130157347
    Abstract: Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools).
    Type: Application
    Filed: July 6, 2012
    Publication date: June 20, 2013
    Applicants: Veridex, LLC, Scripps Health
    Inventors: Eric Topol, Samir Damani, Mark Connelly, Galla Chandra Rao
  • Patent number: 8329422
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CELLSPOTTER® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Grant
    Filed: November 2, 2010
    Date of Patent: December 11, 2012
    Assignee: Veridex LLC
    Inventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
  • Publication number: 20120202189
    Abstract: A novel cytometer system, methods and algorithms which provide a rugged, affordable and easy-to-use device in remote locations. All cells in a biological sample are fluorescently labeled, with target cells also magnetically labeled. Non-magnetically labeled cells are imaged for viability. Labeled sample is placed between two wedge-shaped magnets to selectively move the magnetically labeled cells for observation. A LED illuminates the cells and a CCO camera captures the images of the fluorescent light emitted by the target cells. Image analysis performed with a novel algorithm provides a cell count that can be related to the target cell concentration of the original sample.
    Type: Application
    Filed: April 16, 2008
    Publication date: August 9, 2012
    Inventors: Mark Carle Connelly, Frank A.W. Coumans, Jimmy Page, Galla Chandra Rao, Joseph Jollick, JR.
  • Publication number: 20120094275
    Abstract: A highly sensitive assay is disclosed which combines immunomagnetic enrichment with multiparameter flow cytometric or image cytometry to detect, enumerate and characterize carcinoma cells in the blood. The present invention incorporates the conjugation of different antibodies to the same ferrofluid. This has the effect of making the ferrofluid polyspecific with respect to the antigens that the ferrofluid will bind. The multiple antibodies present on the same ferrofluid do not appear to block or otherwise interfere with each other. Such ferrofluids have the highly desirable effect of being able to bind specifically to more than one type of cell. The assay is especially useful to enable the capture of CTCs that have low EpCAM expression, but high expression of other tumor markers; Accordingly, the assay facilitates the biological characterization and staging of carcinoma cells.
    Type: Application
    Filed: October 13, 2011
    Publication date: April 19, 2012
    Inventors: Galla Chandra Rao, Mark Carle Connelly
  • Publication number: 20110300551
    Abstract: The present invention provides an automated method for capturing and detecting circulating melanoma cells (CMC's) in the blood of patients with melanoma. The absolute number of circulating melanoma cells detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy.
    Type: Application
    Filed: June 8, 2011
    Publication date: December 8, 2011
    Inventors: Galla Chandra Rao, Mark C. Connelly
  • Publication number: 20110104718
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Application
    Filed: November 2, 2010
    Publication date: May 5, 2011
    Applicant: VERIDEX, LLC
    Inventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W.M.M. Terstappen, Shawn Mark O'Hara, Steven Gross
  • Patent number: 7901950
    Abstract: Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.
    Type: Grant
    Filed: February 2, 2007
    Date of Patent: March 8, 2011
    Assignee: Veridex, LLC
    Inventors: Mark Carle Connelly, Gerald V. Doyle, Galla Chandra Rao, Leon W. M. M. Terstappen
  • Patent number: 7863012
    Abstract: The methods and reagents described in this invention are used to analyze circulating tumor cells, clusters, fragments, and debris. Analysis is performed with a number of platforms, including flow cytometry and the CellSpotter® fluorescent microscopy imaging system. Analyzing damaged cells has shown to be important. However, there are two sources of damage: in vivo and in vitro. Damage in vivo occurs by apoptosis, necrosis, or immune response. Damage in vitro occurs during sample acquisition, handling, transport, processing, or analysis. It is therefore desirable to confine, reduce, eliminate, or at least qualify in vitro damage to prevent it from interfering in analysis. Described herein are methods to diagnose, monitor, and screen disease based on circulating rare cells, including malignancy as determined by CTC, clusters, fragments, and debris. Also provided are kits for assaying biological specimens using these methods.
    Type: Grant
    Filed: February 17, 2004
    Date of Patent: January 4, 2011
    Assignee: Veridex, LLC
    Inventors: Galla Chandra Rao, Christopher Larson, Madeline Repollet, Herman Rutner, Leon W. M. M. Terstappen, Shawn Mark O'Hara, Steven Gross
  • Publication number: 20100326587
    Abstract: An improved cartridge for holding a fluid sample with a small volume is disclosed herein. The cartridge has a test chamber and a vestibule through which the test fluids are inserted into the test chamber. Improved grips are flared-out to aid manipulation. The handle portion is reinforced to prevent flexing, and a prefabricated trough along the edge of the land surface prevents introduction of the adhesive into the region for analysis. The cartridge has a stopper having a dual sealing mechanism, which seals the test chamber inlet between the vestibule and the test chamber, and the mouth of the vestibule so that when the stopper is in place, the test chamber is closed to the admission of air or other contaminants. The vestibule is similarly closed against escape of the overflow from the test chamber. The stopper is composed of a single elastomer. An improved locking mechanism has two flexible walls on either side of the handhold that locks into their respective keepers on the cartridge to provide a secure lock.
    Type: Application
    Filed: September 6, 2010
    Publication date: December 30, 2010
    Applicant: VERIDEX, LLC
    Inventors: Michael Kagan, Galla Chandra Rao, Jerry Prohaska, Tor Alden